<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HEF95CE3C90FC4610AA2740865D79D6A7" public-private="public">
	<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>112th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 5283</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20120427">April 27, 2012</action-date>
			<action-desc><sponsor name-id="R000585">Mr. Reed</sponsor> introduced
			 the following bill; which was referred to the
			 <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Public Health Service Act to enhance the
		  clinical trial registry data bank reporting requirements and enforcement
		  measures.</official-title>
	</form>
	<legis-body id="HAE4B6541ADAE417995858884777426DA" style="OLC">
		<section id="H8FE6BBF81A36463182DD0E253A6E6D25" section-type="section-one"><enum>1.</enum><header>Enhancing clinical trial
			 registry data bank reporting requirements and enforcement measures</header>
			<subsection id="H14C14ABEB2454938BF9C4DB8213095BA"><enum>(a)</enum><header>Clarification
			 that clinical trial registry data bank requirements apply regardless of trial
			 outcomes</header><text display-inline="yes-display-inline">Section
			 402(j)(1)(A)(i) of the Public Health Service Act (42 U.S.C. 282(j)(1)(A)(i)) is
			 amended by inserting before the period at the end the following <quote>,
			 whether or not such a clinical trial results in a positive or negative
			 outcome</quote>.</text>
			</subsection><subsection id="HE8E64E818A8F4F68B36B50EB465ED719"><enum>(b)</enum><header>Application to
			 grants from Department of Defense</header><text>Section 402(j)(5)(A)(i) of such
			 Act (42 U.S.C. 282(j)(5)(A)(i)) is amended by inserting <quote>the Department
			 of Defense or</quote> after <quote>agency of</quote>.</text>
			</subsection><subsection id="H8C829161A59F481590AABE17B8EA8BF1"><enum>(c)</enum><header>Enhanced
			 enforcement</header><text display-inline="yes-display-inline">Section
			 402(j)(5)(A) of such Act (42 U.S.C. 282(j)(5)(A)) is amended by adding at the
			 end the following new clause:</text>
				<quoted-block display-inline="no-display-inline" id="H240FD2046DC8488C92C1D48160DAB31E" style="OLC">
					<clause id="H85E154A4149C4070B844ED172C237147"><enum>(v)</enum><header>Enhanced
				enforcement</header><text display-inline="yes-display-inline">After the 30-day
				period described in clause (iii), if the head of an agency referred to in
				clause (i), as applicable, verifies that a grantee has not submitted clinical
				trial information as described in clause (ii), with respect to an applicable
				clinical trial that is funded in whole or in part by a grant from the agency,
				such grantee—</text>
						<subclause id="H5B2918B5D0F04305865844B506470769"><enum>(I)</enum><text>shall not be
				eligible to receive any remaining funding for the grant or funding for a future
				Federal grant until such time as the grantee comes into compliance with all
				applicable reporting requirements under this subsection; and</text>
						</subclause><subclause id="H671F2E7946C44BA0A624912E312A867F"><enum>(II)</enum><text>shall be liable
				to the United States for repayment of any amount provided under the grant for
				the clinical trial for which the grantee failed to comply with such reporting
				requirements.</text>
						</subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection></section></legis-body>
</bill>
